Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Denali Therapeutics Inc has a consensus price target of $38.79 based on the ratings of 22 analysts. The high is $87 issued by HC Wainwright & Co. on February 28, 2025. The low is $24 issued by JP Morgan on January 7, 2025. The 3 most-recent analyst ratings were released by B of A Securities, Morgan Stanley, and B. Riley Securities on March 10, 2025, March 7, 2025, and March 5, 2025, respectively. With an average price target of $32 between B of A Securities, Morgan Stanley, and B. Riley Securities, there's an implied 116.80% upside for Denali Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/10/2025 | Buy Now | 89.7% | B of A Securities | Tazeen Ahmad55% | $30 → $28 | Maintains | Buy | Get Alert |
03/07/2025 | Buy Now | 123.58% | Morgan Stanley | Matthew Harrison60% | $41 → $33 | Assumes | → Overweight | Get Alert |
03/05/2025 | Buy Now | 137.13% | B. Riley Securities | Mayank Mamtani71% | $38 → $35 | Reiterates | Buy → Buy | Get Alert |
03/03/2025 | Buy Now | 184.55% | Oppenheimer | Jay Olson62% | $50 → $42 | Maintains | Outperform | Get Alert |
02/28/2025 | Buy Now | 489.43% | HC Wainwright & Co. | Andrew Fein57% | $80 → $87 | Maintains | Buy | Get Alert |
02/11/2025 | Buy Now | 110.03% | Deutsche Bank | David Hoang42% | → $31 | Initiates | → Buy | Get Alert |
01/28/2025 | Buy Now | 171% | Goldman Sachs | Salveen Richter52% | $45 → $40 | Maintains | Buy | Get Alert |
01/07/2025 | Buy Now | 62.6% | JP Morgan | Jessica Fye68% | $28 → $24 | Maintains | Overweight | Get Alert |
01/07/2025 | Buy Now | 489.43% | HC Wainwright & Co. | Andrew Fein57% | $90 → $87 | Maintains | Buy | Get Alert |
01/07/2025 | Buy Now | 110.03% | Baird | Joel Beatty69% | → $31 | Initiates | → Outperform | Get Alert |
01/03/2025 | Buy Now | — | William Blair | Sarah Schram8% | — | Initiates | → Outperform | Get Alert |
12/16/2024 | Buy Now | 150.68% | Stifel | Paul Mattels7% | → $37 | Upgrade | Hold → Buy | Get Alert |
11/07/2024 | Buy Now | 509.76% | HC Wainwright & Co. | Andrew Fein57% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
11/01/2024 | Buy Now | 204.88% | Jefferies | Michael Yee56% | $40 → $45 | Maintains | Buy | Get Alert |
10/11/2024 | Buy Now | 89.7% | JP Morgan | Jessica Fye68% | $29 → $28 | Maintains | Overweight | Get Alert |
10/10/2024 | Buy Now | — | Raymond James | Danielle Brill43% | — | Reinstates | → Market Perform | Get Alert |
09/09/2024 | Buy Now | 137.13% | Cantor Fitzgerald | Charles Duncan72% | $35 → $35 | Reiterates | Overweight → Overweight | Get Alert |
09/04/2024 | Buy Now | 509.76% | HC Wainwright & Co. | Andrew Fein57% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
09/04/2024 | Buy Now | 96.48% | B of A Securities | Tazeen Ahmad55% | $25 → $29 | Maintains | Buy | Get Alert |
08/15/2024 | Buy Now | 509.76% | HC Wainwright & Co. | Andrew Fein57% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
08/05/2024 | Buy Now | 509.76% | HC Wainwright & Co. | Andrew Fein57% | $95 → $90 | Maintains | Buy | Get Alert |
08/02/2024 | Buy Now | 116.8% | Citigroup | David Hoang42% | $26 → $32 | Maintains | Buy | Get Alert |
08/02/2024 | Buy Now | 76.15% | Wedbush | Laura Chico48% | $30 → $26 | Maintains | Outperform | Get Alert |
07/10/2024 | Buy Now | 96.48% | JP Morgan | Jessica Fye68% | $28 → $29 | Maintains | Overweight | Get Alert |
05/08/2024 | Buy Now | 543.63% | HC Wainwright & Co. | Andrew Fein57% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
05/08/2024 | Buy Now | 103.25% | Wedbush | Laura Chico48% | $31 → $30 | Maintains | Outperform | Get Alert |
05/08/2024 | Buy Now | 49.05% | Stifel | Paul Mattels7% | $26 → $22 | Maintains | Hold | Get Alert |
04/09/2024 | Buy Now | 116.8% | UBS | Esther Rajavelu34% | $70 → $32 | Maintains | Buy | Get Alert |
02/29/2024 | Buy Now | 238.75% | Goldman Sachs | Salveen Richter52% | $73 → $50 | Maintains | Buy | Get Alert |
02/28/2024 | Buy Now | 110.03% | Wedbush | Laura Chico48% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
02/28/2024 | Buy Now | 543.63% | HC Wainwright & Co. | Andrew Fein57% | $105 → $95 | Maintains | Buy | Get Alert |
02/22/2024 | Buy Now | 611.38% | HC Wainwright & Co. | Andrew Fein57% | $105 → $105 | Reiterates | Buy → Buy | Get Alert |
12/13/2023 | Buy Now | 116.8% | Citigroup | David Hoang42% | → $32 | Initiates | → Buy | Get Alert |
11/20/2023 | Buy Now | 89.7% | JP Morgan | Jessica Fye68% | → $28 | Reinstates | → Overweight | Get Alert |
11/08/2023 | Buy Now | 110.03% | Wedbush | Laura Chico48% | → $31 | Reiterates | Outperform → Outperform | Get Alert |
10/24/2023 | Buy Now | 137.13% | Cantor Fitzgerald | Charles Duncan72% | $85 → $35 | Assumes | → Overweight | Get Alert |
09/06/2023 | Buy Now | 157.45% | B. Riley Securities | Mayank Mamtani71% | → $38 | Initiates | → Buy | Get Alert |
08/31/2023 | Buy Now | 611.38% | HC Wainwright & Co. | Andrew Fein57% | → $105 | Reiterates | Buy → Buy | Get Alert |
08/31/2023 | Buy Now | 475.88% | Cantor Fitzgerald | Charles Duncan72% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
08/22/2023 | Buy Now | 475.88% | Cantor Fitzgerald | Charles Duncan72% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
08/10/2023 | Buy Now | 475.88% | Cantor Fitzgerald | Charles Duncan72% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
08/09/2023 | Buy Now | 110.03% | Wedbush | Laura Chico48% | $37 → $31 | Maintains | Outperform | Get Alert |
08/09/2023 | Buy Now | 611.38% | HC Wainwright & Co. | Andrew Fein57% | → $105 | Reiterates | Buy → Buy | Get Alert |
06/22/2023 | Buy Now | 475.88% | Cantor Fitzgerald | Charles Duncan72% | → $85 | Reiterates | Overweight → Overweight | Get Alert |
06/21/2023 | Buy Now | 611.38% | HC Wainwright & Co. | Andrew Fein57% | → $105 | Reiterates | Buy → Buy | Get Alert |
06/06/2023 | Buy Now | 360.7% | Oppenheimer | Jay Olson62% | $70 → $68 | Maintains | Outperform | Get Alert |
05/09/2023 | Buy Now | 150.68% | Wedbush | Laura Chico48% | $38 → $37 | Maintains | Outperform | Get Alert |
05/09/2023 | Buy Now | 611.38% | HC Wainwright & Co. | Andrew Fein57% | → $105 | Reiterates | → Buy | Get Alert |
04/12/2023 | Buy Now | 326.83% | Morgan Stanley | Matthew Harrison60% | $61 → $63 | Maintains | Overweight | Get Alert |
03/02/2023 | Buy Now | 374.25% | Oppenheimer | Jay Olson62% | $85 → $70 | Maintains | Outperform | Get Alert |
03/01/2023 | Buy Now | 313.28% | Morgan Stanley | Matthew Harrison60% | $65 → $61 | Maintains | Overweight | Get Alert |
02/28/2023 | Buy Now | 238.75% | Evercore ISI Group | Joshua Schimmer43% | $80 → $50 | Maintains | Outperform | Get Alert |
02/28/2023 | Buy Now | 611.38% | HC Wainwright & Co. | Andrew Fein57% | → $105 | Reiterates | → Buy | Get Alert |
02/28/2023 | Buy Now | 157.45% | Wedbush | Laura Chico48% | $46 → $38 | Maintains | Outperform | Get Alert |
02/23/2023 | Buy Now | 611.38% | HC Wainwright & Co. | Andrew Fein57% | → $105 | Reiterates | → Buy | Get Alert |
01/30/2023 | Buy Now | 238.75% | SVB Leerink | Marc Goodman74% | → $50 | Initiates | → Outperform | Get Alert |
01/25/2023 | Buy Now | 340.38% | Morgan Stanley | Matthew Harrison60% | $60 → $65 | Maintains | Overweight | Get Alert |
12/05/2022 | Buy Now | — | Cowen & Co. | Brendan Smith36% | — | Initiates | → Outperform | Get Alert |
11/08/2022 | Buy Now | 306.5% | Morgan Stanley | Matthew Harrison60% | $67 → $60 | Maintains | Overweight | Get Alert |
11/02/2022 | Buy Now | 171% | B of A Securities | Avikal Malik3% | → $40 | Initiates | → Buy | Get Alert |
06/23/2022 | Buy Now | 164.23% | Berenberg | Caroline Palomeque60% | → $39 | Initiates | → Buy | Get Alert |
05/24/2022 | Buy Now | 455.56% | Goldman Sachs | Salveen Richter52% | $99 → $82 | Maintains | Buy | Get Alert |
The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by B of A Securities on March 10, 2025. The analyst firm set a price target for $28.00 expecting DNLI to rise to within 12 months (a possible 89.70% upside). 28 analyst firms have reported ratings in the last year.
The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by B of A Securities, and Denali Therapeutics maintained their buy rating.
The last upgrade for Denali Therapeutics Inc happened on December 16, 2024 when Stifel raised their price target to $37. Stifel previously had a hold for Denali Therapeutics Inc.
There is no last downgrade for Denali Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a maintained with a price target of $30.00 to $28.00. The current price Denali Therapeutics (DNLI) is trading at is $14.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.